Study based on metabolomics and network pharmacology to explore the mechanism of Ginseng‐Douch compound fermentation products in the treatment of hyperlipidemia
Journal of the Science of Food and Agriculture · 15.01.2025 · 105 (1) · 611-625
DOI: 10.1002/jsfa.13858 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Science of Food and Agriculture, online erschienen am 12.09.2024. Verfasst von Jianfeng Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chinese Materia Medica, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China. Hauptthemen laut MEDLINE: Hyperlipidemias, Panax, Metabolomics, Network Pharmacology. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Ginseng‐Douchi (GD) is a complex fermented product of ginseng and soybean, similar to natto, and is effective in the treatment of hyperlipidemia, but the mechanism of action involved needs to be further explored. RESULTS The present study combines a comprehensive strategy of network pharmacology and metabolomics to explore the lipid‐lowering mechanism of GD. First, a hyperlipidemia rats model induced by a high‐fat diet was established to evaluate the therapeutic effects of GD. Second, potential biomarkers were identified using serum metabolomics and metabolic pathway analysis was performed with MetaboAnalyst. Third, network pharmacology is used to find potential therapeutic targets based on the blood‐influencing components of GD. Finally, core targets were obtained through a target–metabolite and the enrichment analysis of biomarkers–genes. Biochemistry analysis showed that GD exerted hypolipidemic effects on hyperlipidemic rats. Nineteen potential biomarkers for the GD treatment of hyperlipidemia were identified by metabolomics, which was mainly involved in linoleic acid metabolism, glycerophospholipid metabolism, ether lipid metabolism, alpha‐linolenic acid metabolism and glycosylphosphatidylinositol‐anchor biosynthesis. GD had a callback function for ether lipid metabolism and glycerophospholipid metabolism pathways. Eighteen blood components were identified in serum, associated with 85 potential therapeutic targets. The joint analysis showed that three core therapeutic targets were regulated by GD, including PIK3CA, AKT1 and EGFR. CONCLUSION This study combines serum medicinal chemistry of traditional Chinese medicine, network pharmacology and metabolomics to reveal the regulatory mechanism of GD on hyperlipidemia. © 2024 Society of Chemical Industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chinese Materia Medica, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
- State Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, China.
ORCID-Profile: Jianfeng Sun
Zitieren
APA
Sun, J., Dong, W., Zhao, Y., Sun, G., Chen, L., Huo, J., & Wang, W. (2025). Study based on metabolomics and network pharmacology to explore the mechanism of Ginseng‐Douch compound fermentation products in the treatment of hyperlipidemia. Journal of the Science of Food and Agriculture, 105(1), 611-625. https://doi.org/10.1002/jsfa.13858
Vancouver
Sun J, Dong W, Zhao Y, Sun G, Chen L, Huo J, et al. Study based on metabolomics and network pharmacology to explore the mechanism of Ginseng‐Douch compound fermentation products in the treatment of hyperlipidemia. Journal of the Science of Food and Agriculture. 2025;105(1):611-625. doi:10.1002/jsfa.13858
BibTeX
@article{Sun2025,
author = {Sun, Jianfeng and Dong, Wenting and Zhao, Yuanyuan and Sun, Guodong and Chen, Liyan and Huo, Jinhai and Wang, Weiming},
title = {Study based on metabolomics and network pharmacology to explore the mechanism of Ginseng‐Douch compound fermentation products in the treatment of hyperlipidemia},
journal = {Journal of the Science of Food and Agriculture},
year = {2025},
volume = {105},
number = {1},
pages = {611--625},
doi = {10.1002/jsfa.13858}
}
EUVIMED